SYNkinase’s mission is to provide life-science researchers with access to the world’s most up-to-date library of kinase inhibitors, and small molecule inhibitors of important therapeutic proteins, for drug-discovery research use. With guidance from our founders, who include kinase biology scientists and expert medicinal and synthetic chemists, we have created a library of potent, pure and research-relevant small molecules.
There are more than 150 kinase targeted drugs in clinical trials or development at present. SYNkinase has many of these compounds available for sale as well as a large range of inhibitors described in the literature such as GPCR, TGF-Beta, MAP Kinase, Cell Cycle and epigenetic inhibitors.
SYNkinase is also a primary source manufacturer, backed by a well-respected chemistry research organisation. If we don’t have your preferred small molecule in our catalogue, we can source or manufacture to your custom specifications.
SYNkinase is wholly owned by SYNthesis med chem – A contract research organisation (CRO) with subsidiaries in Australia, China, USA and UK. SYNthesis med chem is a provider of small molecule drug discovery services. Their focus is on the provision of world class medicinal and synthetic chemistry services. They add capacity and insight to the drug discovery programs of their clients by accelerating programs from hit-to-lead through to lead optimisation and beyond.
SYNthesis med chem is managed by an amazing team of experienced biotech professionals.
Please download our latest product catalogue.
For purchases please contact us on service@synmedchem.cn.
